RxDoctor Payments Data

Sunil Santhanakrishnan, MD

Pulmonary Disease · Phoenix, AZNPI 1215991617

Payments from drug & device makers

$11,129in general payments, 2019–2025

Across 528 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$987
  • Actelion Pharmaceuticals US, Inc.$931
  • Electromed, Inc.$874
  • Boehringer Ingelheim$851
  • United Therapeutics Corporation$794
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$10,95698%
  • Education$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,129 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$98,830
Medicare patients
331
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan56$692,888
AdempasRiociguat35$453,225
Orenitram ErTreprostinil Diolamine41$418,282
OfevNintedanib Esylate25$326,790
Tyvaso DpiTreprostinil13$304,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter228$175,493
AdcircaTadalafil13$56,812
Ambrisentan11$43,132
Breo ElliptaFluticasone/Vilanterol50$31,807
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$26,680
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$19,051
Spiriva RespimatTiotropium Bromide21$18,867
Arnuity ElliptaFluticasone Furoate40$15,376
SymbicortBudesonide/Formoterol Fumarate34$14,243
EliquisApixaban20$12,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$931$692,88856 claims
BayerAdempas$234$453,22535 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$851$364,70976 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$987$234,634338 claims
United Therapeutics CorporationAdcirca$794$56,81213 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,173$40,92377 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →